摘要
目的观察曲美他嗪(TMZ)联合培哚普利治疗慢性充血性心力衰竭(CHF)患者的临床疗效。方法90例CHF患者随机单盲分成治疗组和对照组,均给予内科常规抗心衰治疗。对照组加服培哚普利,初始剂量2mg,每日1次,逐渐加至靶剂量4mg,每日1次;治疗组在对照组的基础上接受曲美他嗪20mg/次,3次/d。疗程3个月,观察治疗前后两组患者的血压、左室收缩末期容积(LESV)、左室舒张末期容积(LEDV)、左室射血分数(LVEF)的变化及不良反应。结果治疗后两组心功能较治疗前有明显改善,治疗组临床总有效率为95.6%,较对照组(80.0%)显著提高(P<0.05);两组治疗后血压有明显改善,与治疗前比较差异有统计学意义(P<0.05),且治疗组与对照组比较差异也有统计学意义(P<0.05);超声心动图LVEF、LESV及LEDV均较治疗前有明显改善(P<0.05),但治疗组较对照组改善更为显著(P<0.05)。结论培哚普利与曲美他嗪联合治疗慢性充血性心力衰竭优于单用培哚普利,能提高临床疗效。
Objective To observe the curative effect of perindopril combined with trimetazidine（TMZ）to treat chroniccongestive heart failure （CHF）. Methods Ninety patients with CHF were randomly divided into experimental group and control group. All patients were given conventional medical treatment. Perindopril was added to the control group,the initial dose of 2mg/d,gradually increased to target dose of 4mg/d; Besides Perindopril,trimetazidine was added to the experimental group, 20mg, tid,.3 month later,the curative effect was evaluated. Results The cardiac function in two groups were significant improved. The clinical total effective rate was 95.6% in the experimental group, higher than that in the control group（80.0% ）, and the blood pressure was significantly improved in the two groups（P 〈 0.05 ）. After treatment, LVEF, LESV and LEDV were significant improved than before（P〈 0.05）,with much more improvement in the treatment group（P〈 0.05）. Side effects were both not found in the two groups. Conclusion Combination of trimetazidine and perindopril for CHF is safe, more effective than perindopril used alone.
出处
《中国现代医生》
2009年第21期11-13,共3页
China Modern Doctor
